Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

SHANGHAI, July 17, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization

By: financialpost.com

Jul 18 2024
10
3065 Views

Japan hosts Pacific Island leaders summit to firm cooperation amid growing China influence in region

Trudeau Urged Carney to Join Government, Globe and Mail Says

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Toshiba Launches New Series of eFuse ICs, Electronic Fuses That Can Be Used Repeatedly

Vance to Assail Wall Street in Populist Appeal to GOP Convention

Germany to impose tougher penalties on people who break through airport perimeters

Condor Signs Its First LNG Framework Agreement in Kazakhstan

California first state to get federal funds for hydrogen energy hub to help replace fossil fuels

Dundee Corporation Announces Acquisition of Shares Of Greenheart Gold Inc.

Starmer Starts UK Reset With Europe as Trump and Vance Loom

Asian Stocks to Fall as Chip Selloff Gains Steam: Markets Wrap

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Get Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Related